Skip to Main Content

About Us

The major strength of the YSPORE is the outstanding scientific faculty and clinical investigators and its clinical and basic research resources. The faculty includes over 60 investigators with diverse interests drawn from basic, clinical and population science departments at Yale (Dermatology, Yale Comprehensive Cancer Center/Oncology, Pathology, Surgery, Genetics, Immunology, Epidemiology, Biostatistics, Laboratory Medicine, Chemical & Biomedical Engineering, Therapeutic Radiology, Molecular, Cellular, and Developmental Biology) and outside Yale (Cell Biology, New York University, NY). There is a wide spread expertise in basic and clinical aspects of melanoma, non-melanoma skin cancers, molecular biology, approaches for genome and proteome wide analysis, immunology, oncology, surgery, biostatistics, bioinformatics, behavioral sciences, pathology and dermatopathology. As a group, the investigators are interested in cancer research - over 90% of the Yale investigators are members of the Yale Comprehensive Cancer Center.

The YSPORE is overseen by internal and external board of advisors composed of distinguished investigators with expertise in translational research. The board meets once a year to evaluate the program, and to provide criticism and suggestion to changes. The YSPORE is flexible, and can change direction to ensure excellence, progress and translational results.

SPORE Faculty

  • Director

    Professor of Dermatology, Pathology, and Immunobiology; Director, Yale SPORE in Skin Cancer; Director, Yale Center for Immuno-Oncology; Co-Leader, Cancer Immunology, Yale Cancer Center

    Marcus Bosenberg MD, PhD, is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Cancer Immunology Program of Yale Cancer Center, Director of the Yale Center for Immuno-Oncology, Contact PI of the Yale SPORE in Skin Cancer,  Director of the Center for Precision Cancer Modeling, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine.In his research, Dr. Bosenberg studies factors that regulate anti-cancer immune responses. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new cancer therapies, and how the immune system can be stimulated to fight cancer. He works to translate basic scientific findings into improvements in cancer diagnosis and therapy. He has published over 200 peer-reviewed articles and is a member of the Yale Cancer Center Executive Committee.Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows.
  • Co-Director

    Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; Director, Yale SPORE in Skin Cancer, Yale Cancer Center; Vice Chair for Translational Research, Internal Medicine; Chief, Division of Skin and Kidney Cancer; Associate Cancer Center Director, Education, Training and Faculty Development; Deputy Section Chief, Medical Oncology

    Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drug regimens and biomarkers predictive of response to therapies in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumor and immune cells from patients treated with novel therapies to determine mechanisms of resistance to therapy and mediators of toxicity from immune checkpoint inhibitors. The laboratory also conducts pre-clinical studies to improve treatment regimens for patients with melanoma, renal cell carcinoma or brain metastasis. Learn more about Dr. Kluger>>
  • Sterling Professor of Immunobiology; Investigator, Howard Hughes Medical Institute

    Dr. Flavell is Sterling Professor of Immunobiology at Yale University School of Medicine, and an Investigator of the Howard Hughes Medical Institute. He received his B.Sc. (Honors) in 1967 and Ph.D. in 1970 in biochemistry from the University of Hull, England, and performed postdoctoral work in Amsterdam (1970-72) with Piet Borst and in Zurich (1972-73) with Charles Weissmann. Before accepting his current position in 1988, Dr. Flavell was first Assistant Professor (equivalent) at the University of Amsterdam (1974-79); then Head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and subsequently President and Chief Scientific Officer of Biogen Research Corporation, Cambridge, Massachusetts (1982-88). Dr. Flavell is a fellow of the Royal Society, a member of the National Academy of Sciences as well as the National Academy of Medicine. Richard Flavell uses transgenic and gene-targeted mice to study Innate and Adaptive immunity, T cell tolerance and activation in immunity and autoimmunity,apoptosis, and regulation of T cell differentiation.
  • Professor of Dermatology and Pathology; Director, Yale Dermatopathology Laboratory

    Dr. McNiff received her M.D. from the University of Vermont College of Medicine, and trained in Anatomic and Clinical Pathology at the University of Virginia Health Sciences Center. After completing a fellowship in dermatopathology at the Medical College of Virginia in 1992, Dr. McNiff joined the faculty at the Yale University School of Medicine. Dr. McNiff’s interests and publications are focused on general clinicopathologic correlations in dermatopathology, mycosis fungoides, animal models of lupus erythematosus and graft vs. host disease, and immunofluorescence techniques in dermatopathology. She is a frequent invited speaker at national and international meetings, and is the past President of the American Society of Dermatopathology.
  • Anthony N. Brady Professor of Pathology and Professor of Medicine (Medical Oncology); Director, Yale Cancer Center Tissue Microarray Facility, Pathology; Director, Yale Pathology Tissue Services, Pathology; Director, Physician Scientist Training Program, Pathology Research

    David Rimm is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in Anatomic Pathology and Cytopathology. At Yale since 1994, Dr. Rimm is the Director of Yale Pathology Tissue Services. He serves as the Director of Translational Pathology and the Physician Scientist Training program in Pathology. His lab group focuses on quantitative pathology with projects related to predicting response to therapy or recurrence or metastasis in breast and lung cancer and melanoma and Head and Neck Squamous Cell Carcinoma.  The lab also works on issues related to biospecimen science especially assay standardization. For discovery aspects of biomarker projects, the lab uses high-plex technologies, including Imaging Mass Cytometry and Digital Spatial Profiling. The work is supported by grants from the NIH, BCRF, and sponsored research agreements from biotech and pharma.. He serves on the Immunohistochemistry committee for the College of American Pathologists (CAP) and the AJCC 9th Edition Panel for Tumor Staging in Breast Cancer. He is an author of over 400 peer-reviewed papers and 8 patents with an H-index over 100. He has served on advisory boards for Amgen, Lilly, Novartis, Astra Zeneca, BMS, Danaher, Cepheid, Perkin Elmer, Dako, Ventana, PAIGE.AI and Cell Signaling Technology.
  • Professor of Medicine (Medical Oncology); Clinical Research Leader, Melanoma Program; Co-Leader, Cancer Immunology, Yale Cancer Center; Co-Director, Yale SPORE in Skin Cancer

    Dr. Mario Sznol is a Professor of Medicine (Medical Oncology). Dr. Sznol, formerly with the National Cancer Institute, has an international reputation in cancer drug development. Dr. Sznol's expertise and experience is in cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. He is working to expand the opportunities for clinical trials at the Yale Cancer Center, particularly those focusing on immunotherapy and novel agents.Learn more about Dr. Mario Sznol>>